Britain’s socialized health care system is rationing care again. This time, it is denying patients access to the first new drug developed in half a century for treating lupus:

Analysts may be rethinking their sales forecasts for GlaxoSmithKline’s lupus drug Benlysta after cost regulators for the National Health Service in the UK turned down funding for the drug.

The “cost regulators” in question are the apparatchiks at NICE, Britain’s version of ObamaCare’s IPAB:

In final draft guidances issued by the National Institute for Health and Clinical Excellence [NICE]… concluded that Benlysta (belimumab) could not be considered a cost-effective use of NHS resources for patients with active autoantibody positive systemic lupus.

It would seem that NICE isn’t very nice if you happen to have lupus. But hey, it’s “free” health care, right? That’s way better than “expensive” health care that actually treats sick people.

Comments 1

  1. Marc Brown wrote:

    Well, Germany’s drug watchdog has also not authorised this drug. The problem is it’s not very effective, only works in about one in ten people and is very expensive.

    Posted 04 May 2012 at 10:30 am

Post a Comment

Your email is never published nor shared. Required fields are marked *